Technology & Science
Dec. 10, 2009
FDA Rejects Insomnia Drug
Somaxon Pharmaceuticals Inc. has again been sent back to the drawing board by the Food and Drug Administration over its drug, Silenor, a treatment for insomnia.
Daily Journal Staff Writer
SAN DIEGO - Somaxon Pharmaceuticals Inc. has again been sent back to the drawing board by the Food and Drug Administration over its drug, Silenor, a treatment for insomnia. Somaxon believes that its resubmission in June "adequately addressed" the FDA's concerns, and is seeking a meeting to find out why the drug still doesn't meet the agency's approval standard. Assisting Matt...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In